CI Q2 2025: Exchange Enrollment Falls Below 400K, Growth Concerns
- Integrated Business Model and Synergies: Cigna’s ability to seamlessly manage and monetize its interconnected platforms—Cigna Healthcare, EverNorth’s pharmacy benefit services, and specialty care—creates cross-selling opportunities and improves risk management, which supports a sustainable margin profile during challenging market conditions.
- Innovative GLP-1 Solutions Driving Affordability: The debut of advanced GLP-1 programs, including capped patient out‐of-pocket costs of $200/month, not only improves affordability for employers but also positions Cigna to capture a growing segment of the weight management market.
- Resilient Pricing and Regulatory Strategy: Strong stop loss premium growth (up 13% in the quarter) and proactive engagement with legislative challenges—such as the positive outcome in Arkansas—illustrate Cigna’s adeptness at mitigating regulatory headwinds while preserving client retention and margin recovery.
- Regulatory Uncertainty: The call highlighted an active legislative environment with specific reference to the Arkansas ruling, where state intervention and temporary orders signal risk for future regulatory actions that may disrupt operations and constrain access to services.
- Pressure in the Individual Exchange Business: The company’s strategic shift from aiming for growth to prioritizing margin led to a dramatic drop in individual exchange enrollment—from nearly 1,000,000 customers in 2023 to fewer than 400,000 today—raising concerns about potential long‐term market share and revenue impact.
- Stop Loss Margin Challenges: Although stop loss premiums grew by 13% in Q2 2025, management acknowledged ongoing efforts to improve margins over upcoming renewal cycles, indicating near-term pressure on profitability within this segment.
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Adjusted EPS | FY 2025 | at least $29.60 per share | at least $29.6 | no change |
Evernorth Pre-Tax Adjusted Earnings | FY 2025 | at least $7.2 billion | at least $7.2 billion | no change |
Cigna Healthcare Pre-Tax Adjusted Earnings | FY 2025 | at least $4.125 billion | at least $4.125 billion | no change |
Medical Care Ratio | FY 2025 | 83.2%–84.2% | 83.2% to 84.2% | no change |
Adjusted EPS | Q3 2025 | no prior guidance | Expected to be slightly above 25% of the full-year outlook | no prior guidance |
Evernorth Adjusted Earnings | Q3 2025 | no prior guidance | Expected to be slightly above 25% of the full-year outlook | no prior guidance |
Cigna Healthcare Adjusted Earnings | Q3 2025 | no prior guidance | Expected to be slightly below 25% of the full-year outlook | no prior guidance |
Medical Care Ratio | Q3 2025 | no prior guidance | Expected to be toward the upper end of the full-year range | no prior guidance |
Operating Cash Flow | 2H 2025 | no prior guidance | Expected to show strong cash flow generation in the second half of 2025, with timing-related impacts from Q2 expected to reverse | no prior guidance |
-
Competitive Pricing
Q: How firm is pricing this quarter?
A: Management explained the market remains firm with expectations for higher price increases in 2026, driven by client-specific experience and elevated cost trends, ensuring margins stay robust. -
EverNorth Margins
Q: How did EverNorth margins perform?
A: Leaders noted mixed margin dynamics where specialty services delivered strong fee‐based margins while the distribution side is lower, with client mix and drug mix factors influencing overall performance. -
Stop Loss Growth
Q: What’s the stop loss outlook?
A: The team highlighted a 13% growth in stop loss premiums, with improvements underway through revised cost structures and strong renewal momentum expected to support margins. -
2026 Selling Season
Q: What challenges for 2026 renewals?
A: Management underscored an active selling season with strong multi‐year renewals, particularly from large clients like Prime Therapeutics, and noted a clear regulatory focus, including a favorable court TRO in Arkansas. -
Exchange Adjustments
Q: How are risk adjustments in exchanges handled?
A: They described that risk adjustment numbers were largely built into forecasts, with modest positive adjustments offsetting utilization pressures amid a strategic shift to prioritize margin over growth. -
GLP-One Economics
Q: What’s the update on GLP-one economics?
A: Management recounted that GLP-one contributions are tracking as expected, with recent innovation capping patient costs at $200/month and overall dispensing economics remaining in line with guidance. -
Specialty Distribution
Q: How is the CuraScript business evolving?
A: The leadership emphasized that CuraScript, now a $25B business, is expanding its market in provider-driven specialty services, offering integrated clinical support and inventory management, distinct from traditional wholesalers. -
Retail Reimbursement Models
Q: Are cost-plus models gaining traction?
A: They noted limited appetite for cost-plus arrangements among PBM clients as current incentive models remain more attractive, with no broad shift predicted for government business at this time. -
Integrated PBM Value
Q: What advantage is there in integrated PBM?
A: Management pointed out that linking medical and pharmacy benefits creates a holistic view of patient care, delivering efficiency and improved cost management that competitors may lack.
Research analysts covering Cigna.